Pectolinarin and Pectolinarigenin of Cirsium setidens Prevent the Hepatic Injury in Rats Caused by D-Galactosamine via an Antioxidant Mechanism
Preparation of Pectolinarigenin Pectolinarigenin was obtained by acid hydrolysis of compound 1. In brief, compound 1 was hydrolyzed in 5% H 2 SO 4 in 50% MeOH solution for 3 h under reflux. After cooling, the solution was fractionated with CHCl 3 three times. The CHCl 3 fraction was washed with distilled water twice and concentrated to dryness. The residue was dissolved in MeOH to yield compound 1a, which was identified as pectolinarigenin by spectroscopy (Fig. 1, C 
13)
Experimental Animals Male Sprague-Dawley rats were purchased from Daehan Bio Link Co., allowed to adapt to laboratory conditions (temperature: 20Ϯ2°C, dampness: 40-60%, light/dark cycle: 12 h) for a week, and rats weighing 200Ϯ10 g were used for animal experiments. Animals were fasted for 24 h before the experiment. To avoid variations in enzyme activity during the day, the animals were sacrificed at a fixed time (10:00 a.m.-12:00 p.m.). These experiments were approved by the University of Kyungsung Animal Care and Use Committee. All procedures were conducted in accordance with the "Guide for Care and Use of Laboratory Animals" published by the National Institutes of Health.
Galactosamine-Induced Liver Injury in Rats Liver injury was induced by intraperitoneal injection with D-galactosamine (GalN; 400 mg/kg body weight) (Sigma, St. Louis, MO, U.S.A.) dissolved in saline. Blood was collected from abdominal aortas 24 h after the final GalN injection.
Experimental Design There were 4 groups of animals: untreated (normal, received distilled water), GalN (control), and GalN plus C. setidens extracts (methanol/buthanol/ chroloform fractions; 100, 200 mg/kg, respectively) or pectolinarin (10, 20 mg/kg; 16, 32 mmol/kg)/pectolinarigenin (10, 20 mg/kg; 32, 64 mmol/kg) rats (nϭ9) for 2 consecutive weeks after GalN treatment. The rats were treated orally. Rats were fasted 7 h after the final sample treatment, anesthetized with CO 2 , and blood was collected from the abdominal aorta. Serum was separated by centrifugation at 2500ϫg for 15 min and tested for aspartate transaminase (AST), alanine transaminase (ALT), alkaline phosphatase (ALP), and lactate dehydrogenase (LDH) enzyme activity. Extracted liver was washed with saline for removing blood and contaminants and homogenized with 0.1 M potassium phosphate buffer (pH 7.4). Homogenates were centrifuged at 10000ϫg for 20 min and 105000ϫg for 60 min at 4°C. Cytosolic fractions from the supernatant were used for measurement of Glutathione (GSH), glutathione-S-transferase (GST), glutathione reductase (GR), g-glutamylcysteine synthetase (GCS), and superoxide dismutase (SOD) activities.
Measurement of Serum AST, ALT ALP, LDH, and TBARS AST and ALT were measured using a kit (Asan Pharm. Co., Korea) prepared by Reitman and Frankel. 15) ALP activity was measured using a kit (Asan Pharm. Co.) based on the method of Roos.
16) LDH activity was measured with the method of Kim et al. 17) Lipid peroxidation was measured with thiobarbituric acid reactive substances (TBARS) as a marker of lipid peroxidation using a modification of the method described by Ohkawa et al.
18)
Measurement of Hepatic GSH, GST, GR, GCS, and SOD Measurement of hepatic GSH was determined by a modified method of Gaitonde et al. 19) GST activity was estimated by the method of Habig and Jakoby. 20) GR activity was determined by a modified method of Mize and Langdon. 21) GCS activity was determined by a modified method of Richman and Meister. 22) SOD activity was measured according to the method of Marklund and Marklund. 
RESULTS AND DISCUSSION
The methanol (MeOH) extract was divided into chloroform (CHCl 3 ) and butanol (BuOH) fractions to search for the active fraction. Since the hepatoprotective effect of the BuOH fraction was more potent than the CHCl 3 fraction, we separated the BuOH fraction by column chromatography to yield pectolinarin ( Fig. 1 (1) ), which was identified by spectroscopic evidence. This compound has not been reported in C. setidens. To obtain the aglycone, pectolinarin was hydrolyzed in an acid solution to yield pectolinarigenin ( Fig. 1  (1a) ). The structure was identified by spectroscopic evidence. Compound 1 and 1a were used to hepatoprotective assays.
Aminotransferase mediates the catalysis of amino transfer reactions and is a marker for clinical diagnosis of liver injury. 24) During the low cellular energy, intracellular K ϩ ions leak out and Na BuOH fractions), rats were treated with GalN and the extract fractions. GalN injection increased serum AST and ALT activities significantly compared with the untreated group (Table 1) , and extract treatment ameliorated this increase in a dose-dependent manner. Treatment with MeOH extract and BuOH extract suppressed AST activity by 13.8% and 19.6%, respectively, at 200 mg/kg; and ALT activity by 21.4% and 25.2%, respectively. Treatment with pectolinarin (10, 20 mg/ kg), the primary component of the BuOH fraction, decreased GalN-induced increases in aminotransferase activity by 16.5% and 31.7% (AST), respectively and by 23.3% and 32.3% (ALT), respectively ( Table 2 ). Pectolinarigenin had weaker activity than pectolinarin (Table 2) . Thus, the BuOH extract of C. setidens contain the primary hepatoprotective component, pectolinarin.
GalN treatment increased serum activities of ALT, AST, ALP and LDH. 25) ALP is a hydrolase enzyme responsible for removing phosphate groups from nucleotides and proteins, is produced primarily in the liver and brain, 25) and is a marker of hepatic function. LDH is a general indicator of acute or chronic hepatic damage, as well as determining organ, cell, and tissue condition. GalN treatment increased serum ALP and LDH activities compared with the untreated group, whereas treatment with the MeOH and BuOH extracts reduced this increase ( Table 1 ). The MeOH extract and BuOH fractions (both 200 mg/kg) suppressed ALP activity by 14.4% and 16.9%, respectively, and LDH activity by 28.1% and 45.7%, respectively (Table 1) . Oral administration of 10 and 20 mg/kg of pectolinarin reduced ALP activity by 14.5% and 31.5%, respectively, and LDH activity by 39.6% and 53.2%, respectively (Table 2) . Pectolinarigenin activity was again weaker than pectolinarin. Thus, pectolinarin is the main hepatoprotective component of C. setidens.
GalN treatment significantly increased TBARS levels compared with the untreated group, whereas treatment with the BuOH fraction significantly reduced these levels at 100 and 200 mg/kg ( Fig. 2A) . Pectolinarin and pectolinarigenin were effective as well (Fig. 2B) , indicating that the samples inhibited hepatic lipid peroxidation caused by GalN. GalN treatment significantly reduced GSH levels in the control group compared with the untreated group, but these changes were reduced by administration of the MeOH extract and BuOH fraction (Table 3) . Pectolinarin was again more effective than pectolinarigenin in this assay (Table 4) .
Oxidative stress is probably not the primary cause for GalN-induced hepatic damage, but indirect increases in ROS can induce hepatic damage in vivo 26) and in vitro. 27 ) ROS produced by stress leads to oxidation of cellular lipids and influences the antioxidant defense system, including reducing GSH levels and synthesis. Here, pectolinarin and pectolinarigenin inhibited GalN-induced increases in lipid peroxidation and decreases in GSH levels.
The depletion of hepatocyte GSH content after GalN treatment is caused by the inhibition of glutathione synthesis, either through decreased activity of glutathione synthesizing enzymes or by increased activity of glutathione breakdown enzymes. 28) Here, GalN treatment decreased GR and GCS activity, which was restored by administration of the BuOH extract (Table 3) , as well as pectolinarin and pectolinarigenin (Table 4) . These results suggest that the BuOH extract, pectolinarin, and pectolinarigenin can activate GR and GCS enzymes to prevent the reduction of hepatic GSH content caused by GalN-induced hepatic injury.
GalN significantly decreased GST and SOD levels, and treatment with C. setidens extract increased them. The MeOH extract and BuOH fraction (both 200 mg/kg) increased GST activity by 67.3% and 68.8%, respectively, and SOD activity by 61.3% and 69.8%, respectively (Table 3) . Pectolinarin (10, 20 mg/kg) increased GST activity by 61.4% and 66.1%, respectively, and SOD activity by 77.6% and 82.7%, respectively ( Table 4 ). The significant effect was only seen in SOD activity. The activity of pectolinarigenin was weaker than pectolinarin. Thus, the C. setidens extracts may protect against GalN-induced hepatic injury by antioxidant mechanisms.
In conclusion, a main component of the MeOH extract of C. setidens, pectolinarin, and its aglycone, pectolinarigenin, prevented GalN-induced hepatotoxicity via an antioxidant mechanism. Therefore, these two components could be potential hepatoprotective agents, as could the parent herb, C. setidens.
